Picture the scene. A director of nursing at a 150-patient hospice agency opens her email on a Tuesday morning to find ADR letters requesting records for six GIP stays from the past 90 days. She knows every one of those patients was appropriate. She knows every one of those stays was medically necessary. She was there. She authorized them herself.
But when she pulls the charts to begin building the response, the documentation tells a different story. “Pain uncontrolled” appears in four of the six initial orders. “Patient admitted to GIP for symptom management” appears in three. There are no physician notes on two of the stays for the first 48 hours. Not one chart has a documented plan to step the patient back down to routine home care. The clinical reality was sound. The documentation was not. Three of those claims get denied.
This is the gap between appropriate care and defensible care. And it is exactly where GIP audits live.
Why GIP Gets Audited
For FY 2026, GIP is paid at $1,199.86 per day. Routine home care — the level at which most hospice patients spend most of their time — is paid at $230.83 per day for days 1 through 60. That is roughly a five-to-one rate differential, and it is no secret. CMS and the OIG have flagged GIP as a high-risk billing area for more than a decade. A 2016 OIG report concluded that hospices had inappropriately billed Medicare over $250 million for GIP care in a single year. TPE and UPIC auditors know that history, and what they look at first is the documentation — specifically, whether it proves the patient needed GIP-level care rather than routine home care.
The standard that governs GIP eligibility sounds simple: the patient must require pain control or acute or chronic symptom management that cannot be provided in any other setting. In practice, documenting that standard with enough specificity to survive audit is where agencies consistently fall short.
GIP Is Now a Scored Quality Signal — In Both Directions
Here is what has changed, and why this matters more than it did a few years ago. GIP utilization is no longer only a billing-risk question. It is now baked into how CMS scores and publicly compares your agency through the Hospice Care Index, the claims-based composite measure reported on Care Compare. The HCI combines ten individual indicators into a single 0-to-10 score, and a hospice earns one point for each indicator it satisfies.
Two of those ten indicators turn on GIP — and they pull in opposite directions. Indicator One awards a point to any hospice that provided at least one GIP or continuous-home-care day during the reporting period. The rationale traces back to a 2013 OIG finding that hundreds of hospices provided no GIP at all, raising the question of whether their dying patients were getting adequate symptom management. In other words, an agency that quietly avoids GIP to stay off the audit radar loses a point and signals a possible access-to-care gap. But Indicator Seven, per-beneficiary Medicare spending, is influenced in part by inappropriate GIP billing — the very pattern the 2016 OIG report described. Bill GIP you cannot defend, and you can drive your spending profile in the wrong direction.
Read those two together and the message is clear: you cannot avoid GIP to play it safe, and you cannot lean on it without justification. Appropriate, well-documented GIP is now the goal in two systems at once — audit defense and public quality scoring.
The “Cannot Be Managed in Another Setting” Standard
This is the sentence auditors look for. Not that the patient had uncontrolled pain. Not that the patient needed close monitoring. That the patient’s symptoms could not be adequately managed at the routine home care level. That specific reasoning — or a clinical equivalent that conveys the same meaning — must appear in the documentation or it is essentially absent from the record.
Here is what weak documentation looks like for a GIP authorization:
Patient presenting with uncontrolled pain, 8/10. Admitting to GIP for better symptom management.
Here is what defensible documentation looks like for the same patient:
Patient presenting with escalating pain rated 8/10 despite home opioid regimen of oxycodone 10 mg Q4H, last adjusted three days prior. Family attempted breakthrough dosing twice overnight per plan without sustained relief. Current home support structure — family caregiver working full-time, aide visits four hours per day — cannot safely administer the medication titration or provide the continuous nursing observation required to manage pain at this level. Admitting to GIP for parenteral opioid titration and continuous skilled nursing assessment. Step-down criteria to be reassessed at 48 hours.
Both descriptions represent the same patient. Only one of them answers the auditor’s question.
A Walk-Through with Raymond
Raymond is 64 years old with metastatic pancreatic adenocarcinoma involving the retroperitoneum and celiac plexus — a tumor distribution that produces some of the most severe mixed visceral and neuropathic pain in all of oncology. He has been on hospice at routine home care for about six weeks. His pain was controlled for a while. Then it was not.
Over ten days, the team escalated his regimen aggressively and appropriately: extended-release morphine from 60 mg to 100 mg every twelve hours, plus immediate-release morphine 30 mg every two hours as needed, which he was using six to eight times a day — a total daily morphine-equivalent dose that roughly doubled across that window to well above 350 mg. And yet his pain held at 8 to 9 out of 10. Worse, he developed the warning signs that further opioid escalation is not just failing but backfiring: new myoclonic jerking, worsening diffuse hypersensitivity to touch, and increasing somnolence without any corresponding drop in pain. This is the clinical picture of opioid-induced neurotoxicity and hyperalgesia — a refractory state where the next dose increase buys toxicity, not relief. The palliative literature describes exactly this presentation in advanced cancer, where roughly one in five patients becomes refractory to opioid up-titration.
The team did not jump straight to the hospital. They escalated within the home first — converting Raymond to a continuous subcutaneous infusion of hydromorphone by CADD pump, with a basal rate and a patient-demand dose. This matters, because most hospices can and do run subcutaneous CADD infusions in the home. What most hospices cannot safely set up in the home is a monitored intravenous infusion. And even on the subcutaneous pump, with the basal rate titrated upward, Raymond’s pain remained uncontrolled and his neurotoxicity limited further opioid escalation.
At this point the indicated intervention is a low-dose ketamine “burst” infusion — an NMDA-receptor antagonist used in palliative care specifically for opioid-refractory pain and opioid-induced hyperalgesia, given as a continuous infusion over several days alongside an opioid rotation. Initiating and titrating intravenous ketamine requires reliable IV access and continuous skilled monitoring for dissociation, hallucinations, and hemodynamic effects during the titration window. That combination — IV infusion plus continuous monitored titration — cannot be safely established at the routine home care level. The subcutaneous home option had already been tried and was insufficient; the next appropriate step was intrinsically inpatient-level care. That is precisely the “cannot be managed in another setting” standard, and Raymond was admitted to GIP.
Now watch the difference in the chart. If the authorization reads: “Cancer patient with uncontrolled pain despite opioids. Admit to GIP for IV pain management” — the claim is at risk, because nothing in it explains why home care could not deliver the care.
If the authorization reads instead:
64-year-old with metastatic pancreatic adenocarcinoma, celiac plexus involvement. Pain refractory at 8-9/10 despite escalation of extended-release morphine to 100 mg Q12H plus immediate-release morphine 30 mg Q2H PRN (6-8 doses/day; total daily MME more than doubled over 10 days). Now exhibiting opioid-induced neurotoxicity — myoclonus, hyperalgesia, somnolence without analgesia — precluding further opioid escalation. Home continuous subcutaneous hydromorphone infusion via CADD pump was initiated and up-titrated without adequate relief. Indicated next intervention is a low-dose IV ketamine burst infusion with opioid rotation, requiring IV access and continuous skilled monitoring for dissociation and hemodynamic effects during titration — a level of care that cannot be safely established in the home and that exceeds routine home care capability. Admitting to GIP for monitored IV ketamine initiation and opioid rotation. Step-down to routine home care on a stabilized CADD regimen once pain is controlled and the infusion is weaned; reassess at 48 hours.
— the claim is defensible. The facts are identical. The documentation is not. Notice what the strong note does: it names a specific intervention that is, by its nature, impossible to deliver at home, and it shows the home alternative was actually attempted first. That is the spine of a defensible GIP stay. (Doses here are illustrative; the clinical decision always rests with the treating clinician and the medical director.)
Daily Physician Documentation — and Who Provides It
One of the most consistently cited deficiencies in GIP audit findings is the absence of daily physician documentation. GIP is not a set-and-forget order. There must be ongoing physician documentation of the patient’s condition, the continuing appropriateness of GIP, and the plan to step back down to routine home care. A GIP stay without daily physician documentation reads to an auditor as a stay without medical oversight — and that is a significant vulnerability.
But here is a point of confusion worth clearing up, because it trips up agencies constantly: that daily physician documentation does not have to come from the hospice medical director personally. GIP is frequently delivered in a contracted hospital or skilled nursing facility where the hospice medical director may not hold admitting privileges — and cannot write orders or progress notes there. In that setting the daily physician documentation can come from a hospice physician who does have privileges at the facility, or be coordinated with the facility’s attending physician, as long as the record clearly reflects active physician oversight of the hospice plan of care and the continued need for GIP. What auditors are testing is not a signature line for one specific person; it is whether a physician was genuinely managing the stay. Build the workflow around wherever the patient physically is, and make sure the oversight is documented by someone who can actually be in that building.
Daily notes do not have to be lengthy. They need to address three things: the patient’s current symptom status, whether GIP remains medically necessary, and the progress toward return to routine home care. That demonstrates the authorization is being actively reviewed — not passively extended.
The Step-Down Plan
GIP is designed to be short-term. Stays beyond a handful of days are a well-known trigger for enhanced audit scrutiny. A GIP authorization with no documented plan to return the patient to routine home care signals to an auditor that the agency may be using GIP as a default placement level rather than a time-limited clinical intervention.
The step-down plan does not need to be elaborate. It needs three elements: when the team will reassess, what clinical criteria indicate the patient can safely return to routine home care, and who is responsible for that decision. For Raymond, that is concrete: return to routine home care on a stabilized subcutaneous CADD regimen once his pain is controlled and the ketamine infusion is weaned. Those elements — documented at admission and revisited in each daily note — are what distinguish a defensible GIP stay from an audit-flagged one.
Five Self-Check Questions Before Authorizing Any GIP Stay
- Does the authorization document specifically why routine home care cannot manage these symptoms — not just that the symptoms are severe, but why this setting cannot safely address them?
- Does the record show what was already tried at a lower level of care — the medications, doses, and home interventions that were attempted and proved insufficient?
- Is daily physician documentation built into the stay from day one — and provided by a physician who can actually be where the patient is?
- Is there a documented step-down plan with clinical criteria, a reassessment timeline, and a named decision-maker?
- Would this documentation answer an auditor who asks “why couldn’t this patient stay at routine home care level?” — without a clinician in the room to explain it?
If any answer is no, the documentation needs one more pass before the stay begins. Build the record as if the ADR letter is already on its way — because for GIP, it statistically might be.
Where Hospice Intelligence Fits — and Where It Does Not
Let me be precise here, because this is a place it would be easy to overstate what any tool can do. Hospice Intelligence does not evaluate level-of-care decisions, and it does not flag GIP authorizations. It will not tell you whether your “cannot be managed in another setting” rationale is strong enough, it does not build your daily physician-review framework, and it does not check your step-down plan. Those are clinical and compliance judgments that live entirely with the bedside clinician, the medical director, and your compliance team. Any vendor — including this one — that tells you software will justify your GIP stays is overselling. Walk away from that claim.
What Hospice Intelligence does is narrower and, for GIP, foundational. Every GIP claim sits on top of a more basic question an auditor will also ask: was this patient even eligible for hospice in the first place? That eligibility rests on the recertification documentation supporting the terminal diagnosis. Hospice Intelligence reads a recertification note, cross-references it against the LCD criteria for the patient’s primary diagnosis, and flags eligibility criteria that were not captured — so the nurse can add the detail that applies before the note is finalized and copied into the EMR. The clinical judgment stays with the clinician. The GIP-specific justification stays where it belongs — with your team. What the tool helps strengthen is the underlying eligibility record that a GIP stay is built on.
Take the Next Step
If you want to see how Hospice Intelligence strengthens recertification documentation in a real workflow, visit hospiceintelligence.com or book a demo to see it live.
📅 Book a demo: https://calendar.app.google/NndT5BcD5DY7duDi8
Want this kind of education in your inbox every week? Subscribe at hospiceintelligence.com.
Sources & References
FY 2026 hospice per-diem rates (RHC days 1–60 $230.83; GIP $1,199.86): CMS FY 2026 Hospice Wage Index and Payment Rate Update Final Rule (CMS-1835-F). Hospice Care Index indicators and scoring: CMS Hospice Quality Reporting Program / HCI Technical Report. OIG findings on GIP: “Medicare Hospice: Use of General Inpatient Care” (OEI-02-10-00490, 2013) and “Hospices Inappropriately Billed Medicare Over $250 Million for General Inpatient Care” (OEI-02-10-00491, 2016). Ketamine for opioid-refractory cancer pain and opioid-induced hyperalgesia: palliative-care case literature (e.g., Cureus 2022;14(11):e31662; Jackson et al., J Pain Symptom Manage 2001). Clinical figures in the Raymond example are illustrative; clinical judgment governs.